Skip to main content
. 2015 Nov 24;149(2):372–384. doi: 10.1093/toxsci/kfv249

FIG. 2.

FIG. 2.

Treatment with BAPTA/AM, a membrane-permeable Ca++ chelator, reduced cytotoxicity mediated by DCLF/cytokine cotreatment. HepG2 cells were pretreated with VEH (0.1% DMSO) or BAPTA/AM (10 μM) for 4 h. Cells were then treated with DCLF (250 µM) alone or in combination with TNF (10 ng/ml) and/or IFN (10 ng/ml), and (A) cytotoxicity or (B) caspase-3 activity was measured 24 h later. a, significantly different from corresponding bar within VEH. b, significantly different from corresponding bar within TNF. c, significantly different from Control within a cytokine group. d, significantly different from DCLF without BAPTA/AM within a cytokine group. Data are represented as mean ± SEM of at least 3 experiments. Abbreviations: VEH, vehicle; TNF, tumor necrosis factor-alpha; IFN, interferon-gamma; LDH, lactate dehydrogenase; DCLF, diclofenac; BAPTA/AM, acetoxymethyl-1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid.